Menu Search
Equities

Kubota Pharmaceutical Holdings Co Ltd

4596:TYO

Kubota Pharmaceutical Holdings Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)61.00
  • Today's Change0.00 / 0.00%
  • Shares traded19.30k
  • 1 Year change-18.67%
  • Beta1.6073
Data delayed at least 20 minutes, as of Nov 08 2024 06:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Cash flow in JPYView more

In 2023, cash reserves at Kubota Pharmaceutical Holdings Co Ltd fell by 1.28bn. Cash Flow from Financing totalled 96.58m or 242.14% of revenues. In addition the company used 1.34bn for operations while cash used for investing totalled 45.03m.
Cash flow per share-23.83
Price/Cash flow per share--
Book value per share36.04
Tangible book value per share36.04
More ▼

Balance sheet in JPYView more

Kubota Pharmaceutical Holdings Co Ltd appears to have little financial risk as the company holds a substantial amount of cash on its books. In fact, 0.77% of the market capitalization can be attributed to its 2.66bn and debt could be paid in full if management chose.
Current ratio8.76
Quick ratio8.51
Total debt/total equity0.0642
Total debt/total capital0.0604
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.